Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury

Colaboración

Año: 2024

Escribá, PV; Gil-Agudo, AM; Samsó, JV; Sánchez-Raya, J; Salvador-de la Barrera, SS; Soto-León, V; León-Alvarez, N; Ferrer, BM; Membrilla-Mesa, MD; Galán, CR; Benito-Penalva, J; Montoto-Marqués, A; Rebollo, JM; García, RP; Henares, FG; Miralles, M; Torres, M; Nieto-Librero, AB; Marco, DG; Gómez, C; Jimeno, D; Oliviero, A

Título: SPINAL CORD

• Q1